<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" version="2.0">
<channel>
<title>Curierul Medical, 2016, Vol. 59, No 4</title>
<link>http://repository.usmf.md:80/xmlui/handle/20.500.12710/1130</link>
<description/>
<pubDate>Fri, 01 May 2026 19:17:44 GMT</pubDate>
<dc:date>2026-05-01T19:17:44Z</dc:date>
<item>
<title>Curierul medical. August 2016, Vol. 59, No 4</title>
<link>http://repository.usmf.md:80/xmlui/handle/20.500.12710/16197</link>
<description>Curierul medical. August 2016, Vol. 59, No 4
From its debut in 1958, the journal has striven to support the interests of&#13;
Moldovan medicine concerning the new concepts of its development. The&#13;
Editorial Board warmly welcomes both the readers of and the authors for the&#13;
journal, all those who are enthusiastic in searching the new and more effective&#13;
ways of solving numerous medical problems. We hope that those who want&#13;
to make their contribution into the science of medicine will find our journal&#13;
helpful and encouraging.&#13;
The journal is accredited by the National Council for Accreditation and&#13;
Attestation. The journal publishes official papers, scientific articles, editorials,&#13;
clinical studies and cases, lectures, methodological guides, reviews, brief reports, and correspondence. The journal welcomes articles in English, Romanian and&#13;
Russian. The journal editorial policy provides the prompt publication of papers&#13;
within 12 weeks after receiving them.; De la prima apariţie în 1958, revista susţine şi dezvoltă noile idei în&#13;
domeniul medicinii, în Republica Moldova. Colegiul de redacţie agrează cu&#13;
multă consideraţie atât cititorii cât şi autorii articolelor, pe toţi acei care cu mult&#13;
entuziasm caută noi şi mult mai efective metode de soluţionare a multiplelor&#13;
probleme ale medicinii. Sperăm, că toţi acei care doresc să-şi aducă aportul&#13;
la dezvoltarea ştiinţelor medicale, vor găsi revista noastră utilă şi atractivă.&#13;
Revista este acreditată de către Consiliul Naţional de Acreditare și Atestare.&#13;
Revista publică comunicări oficiale și, totodată, sunt editate diverse publicaţii,&#13;
inclusiv independente: articole știinţifice, editoriale, cercetări și prezentări de&#13;
cazuri clinice, prelegeri, îndrumări metodice, articole de sinteză, relatări scurte,&#13;
corespondenţe și recenzii. Revista publică articole în limba engleză, română și&#13;
rusă. Politica de editare a revistei prevede examinarea operativă și publicarea&#13;
articolelor timp de 12 săptămâni după înaintare.; С первого дня своего выпуска в 1958 году журнал стремится поддерживать и развивать новые идеи в области медицины в Молдове. Редакционная коллегия всегда рада как читателям, так и авторам статей,&#13;
всем тем, кто с энтузиазмом ищет новые, более эффективные способы&#13;
решения многочисленных задач медицины. Мы надеемся, что все те, кто&#13;
хотят внести свой вклад в медицинскую науку, найдут наш журнал полезным и вдохновляющим.&#13;
Журнал аккредитован Высшей Аттестационной Комиссией Республики Молдова. В журнале печатаются официальные материалы, научные статьи, наблюдения из клинической практики, обобщающие статьи,&#13;
краткие сообщения, методические указания, рецензии и корреспонденция. В журнале публикуются статьи на английском, румынском и русском языках. Издательская политика журнала предусматривает оперативное рассмотрение и публикацию статей в среднем в течение 12 недель после поступления.
Fondatori: Ministerul Sănătăţii al Republicii Moldova, Universitatea de Stat de Medicină şi Farmacie “Nicolae Testemiţanu”
</description>
<pubDate>Fri, 01 Jan 2016 00:00:00 GMT</pubDate>
<guid isPermaLink="false">http://repository.usmf.md:80/xmlui/handle/20.500.12710/16197</guid>
<dc:date>2016-01-01T00:00:00Z</dc:date>
</item>
<item>
<title>Segregation of tuberculosis patients by social, demographic and economic features on the model of Chisinau city and the role of community support</title>
<link>http://repository.usmf.md:80/xmlui/handle/20.500.12710/2939</link>
<description>Segregation of tuberculosis patients by social, demographic and economic features on the model of Chisinau city and the role of community support
Lesnic, Evelina; Paladi, Carmina; Niguleanu, Adriana; Ciubotaru, Viorica; Sirbu, Petru; Curocichin, Ghenadie
Background: One of the most important actions in tuberculosis control represents the improvement of social and economic conditions, as well as&#13;
nutrition, hygiene, housing and working state of the population. Commission on Social determinants of Health suggests to all tuberculosis burden&#13;
countries, especially targeting research sector, governments and academia institutions to implement health-oriented interventions, as being the most&#13;
powerful potential efforts in tuberculosis control. The aim of the study was the segregation of tuberculosis patients according to the social, demographic&#13;
and economic characteristics revealed at the regional level in Chisinau city for identifying target groups for improving the earlier case-detection.&#13;
Material and methods: 185 pulmonary tuberculosis patients diagnosed in the period 01.01.2015-31.12.2015 in Chisinau city were investigated.&#13;
Results: While segregating new cases of pulmonary tuberculosis there were identified several high risk groups for active disease: social risk groups with&#13;
specific features – uninsured, unemployed, living in poor conditions; groups with suppressing medical conditions; epidemiologically endangered groups&#13;
– homeless, migrants and contacts with tuberculosis patients; persons with harmful habits (alcohol abusers, injection drug users). Due to enumerated&#13;
risk factors it was identified that one half of patients were late detected as being microscopic positive for acid-fast-bacilli that presented the highest&#13;
epidemiological danger.&#13;
Conclusions: Social and community support must take into account the segregation of TB patients method for improving awareness, education and&#13;
information of high risk groups and specific groups for tuberculosis.
</description>
<pubDate>Fri, 01 Jan 2016 00:00:00 GMT</pubDate>
<guid isPermaLink="false">http://repository.usmf.md:80/xmlui/handle/20.500.12710/2939</guid>
<dc:date>2016-01-01T00:00:00Z</dc:date>
</item>
<item>
<title>The use of medical ozone in dentistry</title>
<link>http://repository.usmf.md:80/xmlui/handle/20.500.12710/2940</link>
<description>The use of medical ozone in dentistry
Pirgari, Andrei
Background: Lately, due to a higher incidence rate of infections, as a result of a decreased immuno-inflammatory response capacity of the human body&#13;
and an expanded role of viral agents in triggering inflammatory diseases, the interest for the use of medical ozone has increased significantly. The reason&#13;
for this growth of popularity lies in the fact that medical ozone has antimicrobial, antiviral, anti-inflammatory, immunomodulatory, antioxidant and&#13;
other properties; it is not a pharmacological product, but rather a “hormetic stress” [18], a pure ecologic physico-chemical factor with multiple biological&#13;
effects [19].&#13;
Conclusions: The action of medical ozone on the human body is diverse and multidirectional. The pharmacological effect of medical ozone represents&#13;
the so-called “hormesis” phenomenon, and this effect is triggered by short chains of hydroxides – hydro-peroxides, also defined as ozone peroxides.&#13;
Medical ozone possesses antalgic, anti-inflammatory, anti-edematous, antioxidant, myorelaxant, detoxing, immunomodulatory, antimicrobial, antiviral,&#13;
antifungal effects, it activates the cellular metabolic processes, stimulates oxygen metabolism and improves rheological properties of blood. In dentistry,&#13;
medical ozone is used on its own or in combination with other treatment methods. At the same time, the aspects of the use of medical ozone in clinical&#13;
periodontology requires additional research.
</description>
<pubDate>Fri, 01 Jan 2016 00:00:00 GMT</pubDate>
<guid isPermaLink="false">http://repository.usmf.md:80/xmlui/handle/20.500.12710/2940</guid>
<dc:date>2016-01-01T00:00:00Z</dc:date>
</item>
<item>
<title>Comparative clinical study of depigmentation products on facial melasma in Latin women</title>
<link>http://repository.usmf.md:80/xmlui/handle/20.500.12710/2933</link>
<description>Comparative clinical study of depigmentation products on facial melasma in Latin women
Orlandi-Jorquera, Cecilia; Moran-Cardenas, María Gabriela; Escobar-Huenchul, Valery Magdalena
Background: Hyperpigmented lesions need the most frequent dermatological consultations, the acquired ones being more effectively treated. Out of&#13;
them, the most common is melasma, which is currently treated with hydroquinone. Our objective was to compare the efficacy of a treatment based on&#13;
Diacetylboldine-DAB, Alpha arbutin and Licorice with hydroquinone 4%.&#13;
Material and methods: We carried out a pilot study on 30 Latin patients (skin type III and IV after Fitzpatrick’s classification). The product under study&#13;
was applied on one side of the face and hydroquinone on the other, during 60 days.&#13;
Results: The study product demonstrated effectiveness comparable to 4% hydroquinone in the 60 days of monitoring time. The hyperpigmentations are&#13;
of a chronic type and so, considering the formula of the study product, it has the great advantage of permitting use for a prolonged period of time without&#13;
the risk of undesirable side effects such as ochronosis. Tolerance for the product was excellent as well, both for daytime and night-time formulations,&#13;
and neither irritation reactions nor allergic reactions were present during the period of use.&#13;
Conclusions: The combined use of active substances is similar and comparable to hydroquinone in a 60 day period. The foundation can be laid for&#13;
future studies to approach a new investigation with a larger number of patients, in which the use of hydroquinone can be established in comparison with&#13;
this new treatment, so as to allow a statistically significant relationship to be established. Additionally, by studying a larger number of participants, it&#13;
would allow this new product to be set up as an effective alternative treatment for melasma.
</description>
<pubDate>Fri, 01 Jan 2016 00:00:00 GMT</pubDate>
<guid isPermaLink="false">http://repository.usmf.md:80/xmlui/handle/20.500.12710/2933</guid>
<dc:date>2016-01-01T00:00:00Z</dc:date>
</item>
</channel>
</rss>
